Bisphosphonates (BPs) are the most commonly used medications for osteoporosis. This
ASBMR report provides guidance on BP therapy duration with a risk‐benefit perspective …

Patients with chronic kidney disease (CKD) exhibit tremendously elevated risk for
cardiovascular disease, particularly ischemic heart disease, due to premature vascular and …

Treatment of Low Bone Density or Osteoporosis to Prevent Fractures in Men and Women: A
Clinical Practice Guideline Update From the American College of Physicians | Annals of Internal …

European guidance for the diagnosis and management of osteoporosis in postmenopausal
women | Osteoporosis International Skip to main content SpringerLink Account Menu Find a …

Guidance is provided in a European setting on the assessment and treatment of
postmenopausal women at risk from fractures due to osteoporosis. Introduction The …

A guidance on the assessment and treatment of postmenopausal women at risk from
fractures due to osteoporosis was recently published in Osteoporosis International as a joint …

Background: Osteoporosis is a major contributor to the propensity to fracture among older
adults, and various pharmaceuticals are available to treat it. Purpose: To update a review …

Vascular calcification is highly prevalent in patients with chronic kidney disease (CKD) and
increases mortality in those patients. Impaired calcium and phosphate homeostasis …

Vascular calcification (VC) is highly correlated with cardiovascular disease morbidity and
mortality, but anti-VC treatment remains an area to be tackled due to the ill-defined …

Patients with chronic kidney disease (CKD) are highly susceptible to cardiovascular (CV)
complications, thus suffering from clinical manifestations such as heart failure and stroke. CV …